TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01405573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400 mg twice a day
Study: NCT03238534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neobianacid®
Description: Oral administrations of Neobianacid® (30' after meals and on demand)
Study: NCT03125603

Intervention type: OTHER
Intervention: Consultation of the patient's medical files at the hospital
Description: Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
Study: NCT02810990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: Bosutinib is given orally accordingly with this scheme:~A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16~At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).~Bosutinib dose is then managed as follows :~C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 \> 1% at week 12: 400 mg OD from week 17 to week 52~All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns).
Study: NCT01128985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Description: 50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: 100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: 300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
Study: NCT03238534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole 20mg
Description: Daily administration Omeprazole 20mg (per os, 30' before breakfast).
Study: NCT01287754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg daily orally
Study: NCT00925847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
Study: NCT00295945

Intervention type: DRUG
Intervention: fentanyl citrate

Intervention type: DRUG
Intervention: hydromorphone hydrochloride

Intervention type: DRUG
Intervention: ropivacaine hydrochloride
Study: NCT00312858

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: VAQTA™ (Hepatitis A vaccine)
Description: VAQTA™ 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: VAQTA™ (Hepatitis A vaccine)
Description: VAQTA™ 0.5 mL injection
Study: NCT01599559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: observation
Description: observation
Study: NCT03238534

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neobianacid® placebo
Description: Oral administrations of Neobianacid® placebo (30' after meals and on demand)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omeprazole placebo
Description: Daily administration Omeprazole placebo (per os, 30' before breakfast).
Study: NCT00312858

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)
Description: ProQuad™ 0.5 mL injection
Study: NCT01599559

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-Conformal Radiotherapy (3D-CRT)
Description: Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
Study: NCT01367080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWETR10
Description: Amitriptyline hydrochloride 10mg(DWETR10) single dose
Study: NCT00482144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDL 450 microseconds
Description: The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
Study: NCT03696784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR19 T cells
Description: iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.
Study: NCT00482144

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PDL 1.5 milliseconds
Description: The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
Study: NCT03696784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9-CAR19 T cells
Description: iC9-CAR19 T cells will be given by a licensed healthcare provider via intravenous injection over 5-10 minutes through either a peripheral or a central line.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.
Study: NCT03696784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: 70mg/m2 IV given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2 given as a daily infusion for 3 days per institutional guidelines 2 - 14 days prior to the T cell infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: 0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: 0.4 mg/kg of AP1903 as an IV infusion over 2 hrs for subjects who develop Grade 4 cytokine release syndrome (CRS) or grade ≥3 CRS that is unresponsive to standard of care interventions , subjects who develop grade ≥3 Immune effector cell-associated neurotoxicity syndrome (ICANS) that does not improve to grade ≤1 within 72 hours with standard of care interventions, and subjects with grade 4 ICANS of any duration that have evidence of cerebral edema and/or generalized convulsive status epilepticus.~Subjects in the expansion cohort who experience ≥ grade 2 CRS or ICANS that remains ≥ grade 2, twenty-four hours after an initial dose of the standard of care treatment may be part of the sub-study of rimiducid. These subjects will receive one of two assigned dose levels. DL1 and DL2 doses are 0.05 mg/kg and 0.01 mg/kg for subjects and DL1: 0.1 mg/kg and DL2: 0.01 mg/kg for subjects with ICANS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2/day administered by IV over 3 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2/day administered by IV over 3 consecutive days
Study: NCT01020422

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty
Description: Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
Study: NCT06199739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early-Weight bearing
Description: The patients began early weight bearing under attending physician and physiotherapist surveillance within 48 hours after surgery. Patients were instructed to stand up near the bed, and muscle power, gait stability, and pain tolerance were recorded. The physiotherapist instructed the patients to perform early mobilization and weight bearing as tolerable by self-adjustment of body weight distribution over the bilateral lower extremities, and walking assistance was used to prevent repeat falling accidents.
Study: NCT03061942

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair without synovectomy
Description: 30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair with synovectomy
Description: 30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
Study: NCT01562990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, CMC544, Gemcitabine and Oxaliplatine
Description: 2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.~2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.
Study: NCT03528031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Daily Avocado
Description: Participants follow their usual diet and lifestyle but also are provided with 1 avocado to consume per day for 6 months.
Study: NCT03611543

Intervention type: DEVICE
Intervention: New investigational curved paddle
Description: X-ray imaging of breast tissue

Intervention type: DEVICE
Intervention: New investigational curved paddle
Description: X-ray imaging of breast tissue
Study: NCT03773588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closed-Loop propofol Target controlled infusion by Entropy and SPI
Description: Closed loop target infusion of propofol using BD TCI pumps guided by entropy and Surgical pleth index

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop propofol target controlled infusion
Description: Propofol target controlled infusion using Schnider algorithm to determine effect site concentration
Study: NCT01184911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Description: Sulfadoxine-pyrimethamine tablets, once
Study: NCT03261401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received placebo matched to M5717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M5717
Description: Participants received single ascending oral dose of M5717 from Part A after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
Study: NCT04118400

Intervention type: PROCEDURE
Intervention: NIV-NAVA
Description: NAVA mode during Non-invasive ventilation

Intervention type: PROCEDURE
Intervention: Nasal CPAP or NIMV mode
Description: Nasal CPAP or NIMV mode during Non-invasive ventilation
Study: NCT01367080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWETR25
Description: Amitriptyline hydrochloride 25mg(DWETR25) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWETR25
Description: Amitriptyline hydrochloride 25mg(DWETR25) single dose
Study: NCT00853996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acolbifene hydrochloride
Description: Given orally
Study: NCT02538783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Escalating Lottery
Description: Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
Study: NCT02439333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)
Description: Nasal high flow therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal catheter or Venturi mask
Description: Conventional oxygen therapy
Study: NCT03452527

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: ICON-1 0.6 mg by intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICON-1
Description: ICON-1 0.6 mg by intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: aflibercept 2 mg by intravitreal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: aflibercept 2 mg by intravitreal injection
Study: NCT03255330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizol
Description: Standardized treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Standardized treatment
Study: NCT00312858

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)
Description: ProQuad™ 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
Description: Prevnar™ 0.5 mL injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)
Description: Prevnar™ 0.5 mL injection
Study: NCT02604836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Film-coated oral ibandronate tablet (150 mg) once-monthly
Study: NCT04221815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eagle Eye Platinum digital IVUS catheter with optional SyncVision
Description: IVUS catheter
Study: NCT03818269

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subcutaneous pressure measurement
Description: Subcutaneous interstitial measurement at D1 and D2

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subcutaneous pressure measurement
Description: Subcutaneous interstitial measurement at D1 and D2
Study: NCT00382967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DaTSCAN SPECT imaging
Description: A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
Study: NCT04221815

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Resolute Onyx Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Onyx Frontier Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onyx Frontier Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Onyx TruStar Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onyx TruStar Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Onyx TruCor Drug Eluting Stent
Description: Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Onyx TruCor Drug Eluting Stent
Description: Stent
Study: NCT00548041

Intervention type: OTHER
Group type: OTHER
Intervention: HIV test by oral swab
Description: Eligible subjects underwent rapid HIV testing by oral swab.
Study: NCT01087723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Study: NCT02416869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular application
Description: Patient receive 4mg of Dexamethasone by intramuscular application

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Submucosal application
Description: Patients receive 4mg of Dexamethasone by submucosal application
Study: NCT01087723

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Study: NCT03638635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Abdominal injection of bupivacaine into fascial layer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposome
Description: Abdominal injection of bupivacaine liposome into fascial layer.
Study: NCT00252590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Motivational Feedback
Description: Personalized feedback on health status

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Generalized health education related to alcohol use

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - treatment as usual
Description: Control group with no additional intervention
Study: NCT00802659

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy
Description: This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
Study: NCT04762329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manage My Pain (MMP) digital pain app group
Description: To evaluate the extent of patient engagement with the Manage My Pain (MMP) digital application when used in a clinical setting
Study: NCT01226979

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose endorectal brachytherapy (HDRBT)
Description: The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
Study: NCT04122560

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 200mg tab
Description: PO dose of 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 200mg tab
Description: PO dose of 400mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole 2 MG/ML
Description: IV dose of 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole 2 MG/ML
Description: IV dose of 400mg